Abstract
Since tenascin C is a factor expressed highly in the tumor-associated matrix, it would be a desirable first step for targeting the tumor-specific microenvironment. In fact, a high level of tenascin C expression has been reported in most solid tumors, including lung cancer, colon cancer and glioblastoma. Therefore, the targeted binding of tenascin C in tumor stroma would inhibit tumor metastasis by modulating cancer cell growth and migration. We isolated a peptide that bound to tenascin C by phage display peptide library selection, and the selected peptide specifically recognized tenascin C protein in xenograft mouse tissue. We also observed exclusive staining of tenascin C by the selected peptide in tumor patient tissues. Moreover, the peptide reduced tenascin C-induced cell rounding and migration. We propose that the tenascin C targeting peptide may be useful as a specific anti-cancer diagnostic and therapeutic tool for most human solid tumors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adams, M., Jones J.L., Walker, R.A., Pringle, J.H., and Bell, S.C. (2002). Changes in tenascin C isoform expression in invasive and preinvasive breast disease. Cancer Res. 62, 3289–3297.
Aggarwal, S., Singh, P., Topaloglu, O., Isaacs, J.T., and Denmeade, S.R. (2006). A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res. 66, 9171–9177.
Akabani, G., Reardon, D.A., Coleman, R.E., Wong, T.Z., Metzler, S.D., Bowsher, J.E., Barboriak, D.P., Provenzale, J.M., Greer, K.L., DeLong, D., et al. (2005). Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J. Nucl. Med. 46, 1042–1051.
Bellofiore, P., Petronzelli, F., De Martino, T., Minenkova, O., Bombardi, V., Anastasi, A.M., Lindstedt, R., Felici, F., De Santis, R., and Verdoliva, A. (2006). Identification and refinement of a peptide affinity ligand with unique specificity for a monoclonal antitenascin C antibody by screening of a phage display library. J. Chromatogr. A 1107, 182–191.
Berndt, A., Anger, K., Richter, P., Borsi, L., Brack, S., Silacci, M., Franz, M., Wunderlich, H., Gajda, M., Zardi, L., et al. (2006). Differential expression of tenascin C splicing domains in urothelial carcinomas of the urinary bladder. J. Cancer Res. Clin. Oncol. 132, 537–546.
Brack, S.S., Silacci, M., Birchler, M., and Neri, D. (2006). Tumortargeting properties of novel antibodies specific to the large isoform of tenascin C. Clin. Cancer Res. 12, 3200–3208.
Chiquet-Ehrismann, R. (2004). Tenascins. Int. J. Biochem. Cell Biol. 36, 986–990.
Chiquet-Ehrismann, R., and Tucker, R.P. (2004). Connective tissues: signaling by tenascins. Int. J. Biochem. Cell Biol. 36, 1085–1089.
Fidler, I.J., Balasubramanian, K., Lin, Q., Kim, S.W., and Kim, S. (2010). The brain microenvironment and cancer metastasis. Mol. Cells 30, 93–98.
Grifman, M., Trepel, M., Speece, P., Gilbert, L.B., Arap, W., Pasqualini, R., and Weitzman, M.D. (2001). Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol. Ther. 3, 964–975.
Hajitou, A., Pasqualini, R., and Arap, W. (2006). Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc. Med. 16, 80–88.
Hicke, B.J., Marion, C., Chang, Y.F., Gould, T., Lynott, C.K., Parma, D., Schmidt, P.G., and Warren, S. (2001). Tenascin C aptamers are generated using tumor cells and purified protein. J. Biol. Chem. 276, 48644–48654.
Hicke, B.J., Stephens, A.W., Gould, T., Chang, Y.F., Lynott, C.K., Heil, J., Borkowski, S., Hilger, C.S., Cook, G., Warren, S., et al. (2006). Tumor targeting by an aptamer. J. Nucl. Med. 47, 668–678.
Hsia, H.C., and Schwarzbauer, J.E. (2005). Meet the tenascins: multifunctional and mysterious. J. Biol. Chem. 280, 26641–26644.
Jäger, S., Jahnke, A., Wilmes, T., Adebahr, S., Vögtle, F.N., Delima-Hahn, E., Pfeifer, D., Berg, T., Lübbert, M., and Trepel, M. (2007). Leukemia targeting ligands isolated from phage display peptide libraries. Leukemia 21, 411–420.
Juuti, A., Nordling, S., Louhimo, J., Lundin, J., and Haglund, C. (2004). Tenascin C expression is upregulated in pancreatic cancer and correlates with differentiation. J. Clin. Pathol. 57, 1151–1155.
Khandare, J.J., and Minko, T. (2006). Antibodies and peptides in cancer therapy. Crit. Rev. Ther. Drug Carrier Syst. 23, 401–435.
Lee, S.M., Lee, E.J., Hong, H.Y., Kwon, M.K., Kwon, T.H., Choi, J.Y., Park, R.W., Kwon, T.G., Yoo, E.S., Yoon, G.S., et al. (2007). Targeting bladder tumor cells in vivo and in the urine with a peptide identified by phage display. Mol. Cancer Res. 5, 11–19.
Orend, G. (2005). Potential oncogenic action of tenascin C in tumorigenesis. Int. J. Biochem. Cell Biol. 37, 1066–1083.
Orend, G., and Chiquet-Ehrismann, R. (2006). Tenascin C induced signaling in cancer. Cancer Lett. 244, 143–163.
Rasmussen, U.B., Schreiber, V., Schultz, H., Mischler, F., and Schughart, K. (2002). Tumor cell-targeting by phage-displayed peptides. Cancer Gene Ther. 9, 606–612.
Reardon, D.A., Akabani, G., Coleman, R.E., Friedman, A.H., Friedman, H.S., Herndon, J.E. 2nd, Cokgor, I., McLendon, R.E., Pegram, C.N., Provenzale, J.M., et al. (2002). Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. 20, 1389–1397.
Silacci, M., Brack, S.S., Späth, N., Buck, A., Hillinger, S., Arni, S., Weder, W., Zardi, L., and Neri, D. (2006). Human monoclonal antibodies to domain C of tenascin C selectively target solid tumors in vivo. Protein Eng. Des. Sel. 19, 471–478.
Takeda, A., Otani, Y., Iseki, H., Takeuchi, H., Aikawa, K., Tabuchi, S., Shinozuka, N., Saeki, T., Okazaki, Y., and Koyama, I. (2007). Clinical significance of large tenascin C spliced variant as a potential biomarker for colorectal cancer. World J. Surg. 31, 388–394.
Tavazoie, S.F., Alarcón, C., Oskarsson, T., Padua, D., Wang, Q., Bos, P.D., Gerald, W.L., and Massagué, J. (2008). Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451, 147–152.
White, S.J., Nicklin, S.A., Büning, H., Brosnan, M.J., Leike, K., Papadakis, E.D., Hallek, M., and Baker, A.H. (2004). Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-assocoated virus vectors. Circulation 109, 513–519.
Author information
Authors and Affiliations
Corresponding author
Additional information
These authors contributed equally to this work.
About this article
Cite this article
Kim, M.Y., Kim, O.R., Choi, Y.S. et al. Selection and characterization of tenascin C targeting peptide. Mol Cells 33, 71–77 (2012). https://doi.org/10.1007/s10059-012-2214-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10059-012-2214-4